BCTXF News and Press, BriaCell Therapeutics

Clinical and pathological findings from clinical trial of the Bria-IMT™ regimen alone and in combination with immune checkpoint inhibitors in advanced breast cancer will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2021, April 10-15 and May...

BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 26, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (TSX-V:BCT) (NASDAQ: BCTX, BCTXW) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies f...

BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 23, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (TSX-V:BCT) (NASDAQ: BCTX, BCTXW) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies f...

Clinical and pathological findings presented from the clinical trials of Bria-IMT™ alone or in combination with immune checkpoint inhibitors in advanced breast cancer: Median overall survival of 12.5 months in patients with moderately-well differentiated ...

BriaCell Therapeutics (BCTXF) intends to offer 2.8M common units in a underwritten offering at $5/unit; each unit consists of a common share and a warrant to purchase one share.It has an estimated price range of $4.25 and $5.25 per common unit.It is also offering 2.8M pre-funded units, each c...

Clinical and pathological data from clinical trial of the Bria-IMT™ regimen alone or in combination with immune checkpoint inhibitors in advanced breast cancer will be presented at the Keystone Symposia, Jan. 25-27, 2021 BERKELEY, Calif. and VANCOUVER, British Colum...

Click here to read the previous biotech outlook. Investors looking at long-term developmental plays with a significant medical impact are well aware of the biotech investment proposal. After a year centered on addressing challenges related to the global COVID-19 pandemic...

Disease control and survival data is presented from the clinical trials of Bria-IMT™ alone or in combination with immune checkpoint inhibitors in advanced breast cancer: M aximum tumor re duction ...

BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 01, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF ) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is ple...

BERKELEY, Calif., and VANCOUVER, British Columbia, Nov. 17, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (" BriaCell " or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast ...